150 related articles for article (PubMed ID: 38626366)
1. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B; Emechebe N; Manzoor BS; Jawaid D; Alhasani H; Edwards M; Tuncer HH
JCO Oncol Pract; 2024 Apr; ():OP2300630. PubMed ID: 38626366
[TBL] [Abstract][Full Text] [Related]
2. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
4. Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study.
Ghosh N; Emond B; Lafeuille MH; Côté-Sergent A; Lefebvre P; Huang Q
Clin Ther; 2021 Aug; 43(8):1285-1299. PubMed ID: 34332789
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax.
Rogers KA; Emond B; Manceur AM; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
Curr Med Res Opin; 2021 Aug; 37(8):1409-1420. PubMed ID: 34003049
[TBL] [Abstract][Full Text] [Related]
6. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy.
Emond B; Sundaram M; Romdhani H; Lefebvre P; Wang S; Mato A
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):763-775.e2. PubMed ID: 31678080
[TBL] [Abstract][Full Text] [Related]
8. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M; Manzoor BS; Sail K; Tuncer HH; Allan JN; Ujjani C; Emechebe N; Kamalakar R; Coombs CC; Leslie L; Barr PM; Brown JR; Eyre TA; Rampotas A; Schuh A; Lamanna N; Skarbnik A; Roeker LE; Bannerji R; Eichhorst B; Fleury I; Davids MS; Alhasani H; Jiang D; Hill BT; Schuster SJ; Brander DM; Pivneva I; Burne R; Guerin A; Mato AR
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):515-526. PubMed ID: 37076367
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
Yin S; Zheng X; Zhang W; Zhao H; Zhang R; Li W; Chen F
Ann Hematol; 2023 Oct; ():. PubMed ID: 37843620
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
Mato AR; Roeker LE; Jacobs R; Hill BT; Lamanna N; Brander D; Shadman M; Ujjani CS; Yazdy MS; Perini GF; Pinilla-Ibarz JA; Barrientos J; Skarbnik AP; Torka P; Pu JJ; Pagel JM; Gohil S; Fakhri B; Choi M; Coombs CC; Rhodes J; Barr PM; Portell CA; Parry H; Garcia CA; Whitaker KJ; Winter AM; Sitlinger A; Khajavian S; Grajales-Cruz AF; Isaac KM; Shah P; Akhtar OS; Pocock R; Lam K; Voorhees TJ; Schuster SJ; Rodgers TD; Fox CP; Martinez-Calle N; Munir T; Bhavsar EB; Bailey N; Lee JC; Weissbrot HB; Nabhan C; Goodfriend JM; King AC; Zelenetz AD; Dorsey C; Bigelow K; Cheson BD; Allan JN; Eyre TA
Clin Cancer Res; 2020 Jul; 26(14):3589-3596. PubMed ID: 32198151
[TBL] [Abstract][Full Text] [Related]
11. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
[TBL] [Abstract][Full Text] [Related]
12. Approaches for relapsed CLL after chemotherapy-free frontline regimens.
Roeker LE; Mato AR
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):10-17. PubMed ID: 33275712
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
14. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
15. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
16. Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
Huntington SF; Manzoor BS; Puckett JT; Kamal-Bahl S; Alhasani H; Ravelo A; Jawaid D; Doshi JA
Leuk Lymphoma; 2023 Dec; 64(14):2316-2323. PubMed ID: 37732602
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis.
Nguyen TT; Nhu NT; Tran VK; Viet-Nhi NK; Ho XD; Jhan MK; Chen YP; Lin CF
Sci Rep; 2023 Jun; 13(1):9775. PubMed ID: 37328530
[TBL] [Abstract][Full Text] [Related]
18. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
Huntington SF; Cheng WY; Sarpong EM; Leng S; Farooqui MZH; Agu US; Catillon M; Lejeune D; Downes N; Matay L; Duh MS; De Nigris E
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38696747
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis.
Nguyen TT; Nhu NT; Tran VK; Nguyen TTH; Lin CF
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046657
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]